Learn About Appendix Cancer

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Appendix Cancer Local Doctors?
KT
Dr. Kiran K. Turaga
Surgical Oncology | General Surgery
Elite
Highly rated in
13
conditions
Surgical Oncology
General Surgery

UChicago Medicine

Duchossois Center For Advanced Medicine (DCAM) - Hyde Park

5758 S Maryland Ave 
Chicago, IL 60637

Kiran Turaga is a Surgical Oncologist and a General Surgeon in Chicago, Illinois. Dr. Turaga has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of Appendix Cancer. He is also highly rated in 13 other conditions, according to our data. His top areas of expertise are Appendix Cancer, Pseudomyxoma Peritonei, Colorectal Cancer, and Familial Colorectal Cancer. He is board certified in Surgical Oncology and licensed to treat patients in Wisconsin, Florida, and Nebraska. Dr. Turaga is currently accepting new patients.

View Profile
EL
Dr. Edward A. Levine
General Surgery | Surgical Oncology
Elite
Highly rated in
25
conditions
General Surgery
Surgical Oncology

Atrium Health Wake Forest Baptist

Wake Forest Baptist Medical Center

Medical Center Blvd 
Winston Salem, NC 27157

Edward Levine is a General Surgeon and a Surgical Oncologist in Winston Salem, North Carolina. Dr. Levine has been practicing medicine for over 37 years and is rated as an Elite doctor by MediFind in the treatment of Appendix Cancer. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Appendix Cancer, Pseudomyxoma Peritonei, Breast Cancer, and Inflammatory Breast Cancer. He is board certified in General Surgery and licensed to treat patients in North Carolina. Dr. Levine is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
KF
Dr. Keith F. Fournier
Surgical Oncology | General Surgery
Elite
Highly rated in
8
conditions
Surgical Oncology
General Surgery

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Keith Fournier is a Surgical Oncologist and a General Surgeon in Houston, Texas. Dr. Fournier has been practicing medicine for over 22 years and is rated as an Elite doctor by MediFind in the treatment of Appendix Cancer. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Appendix Cancer, Pseudomyxoma Peritonei, Colorectal Cancer, and Familial Colorectal Cancer. He is board certified in Surgical Oncology and General Surgery and licensed to treat patients in Texas. Dr. Fournier is currently accepting new patients.

View Profile
View All Doctors
What are the Latest Advances for Appendix Cancer?
Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
Condition: Low-grade Appendiceal Tumors
Journal: Anticancer research
Treatment Used: Heated Intra-Peritoneal Chemotherapy and Early Postoperative Intra-Peritoneal Chemotherapy
Number of Patients: 238
Published: November 04, 2021
View publication
Summary: Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Condition: Pseudomyxoma Peritonei (PMP)
Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Treatment Used: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Number of Patients: 41
Published: September 26, 2021
View publication
Summary: Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Tired of the same old research?
Check Latest Advances
Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix.
Condition: Mucinous Adenocarcinoma of Appendix
Journal: Oncology (Williston Park, N.Y.)
Treatment Used: Neoadjuvant Chemotherapy
Number of Patients: 1
Published: June 23, 2021
View publication
Summary: Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix.
View All Latest Advances
What are the latest Appendix Cancer Clinical Trials?
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Who is this study for: Patients with Cancer
Status: Recruiting
Start Date: October 19, 2021
Intervention Type: Drug, Procedure
Study Drugs: Oxaliplatin, Daunorubicin, Doxorubicin, Cisplatin
Phase: Phase 1
View Trial
Summary: Background:~Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is heated chemotherapy that washes the abdomen. CRS and HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve results of CRS and HIPEC by choosing the chemotherapy drugs used in HIPEC.~Objective:~To see if...
Match to trials
Find the right clinical trials for you in under a minute
Get started
Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix: An International Multicenter Study
Status: Recruiting
Start Date: October 1, 2020
Intervention Type: Other
View Trial
Summary: The aim of the present project is to evaluate the frequency of distant metastases and clinically relevant relapse and mortality, respectively, of aNEN (Neuroendocrine Neoplasms of the Appendix) measuring 1 - 2 cm.~The investigators hypothesize that the mortality rate of aNET (Neuroendocrine Tumors of the Appendix) measuring 1 - 2cm is less than 1%. Furthermore, the investigators hypothesize that r...
View All Clinical Trials